Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

The new therapy, made from the pancreatic cells of deceased donors, is designed to help adult type 1 diabetes with severe hypoglycemia go a year or longer without needing to take insulin. 

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

High out-of-pocket costs are a growing problem in healthcare, often creating stress and confusion for patients. A new analysis in Circulation: Cardiovascular Quality and Outcomes examined one way that physicians can help. 

Researchers examined data from more than 900 patients, presenting their findings in the Journal of the American Heart Association.

The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.

Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly's CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 

Insilico Medicine, a clinical stage AI-drive drug discovery company, has penned a multi-year, multi-target strategic research collaboration with Sanofi in a deal valued at $1.2 billion.